Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷
Otsuka Pharmaceutical Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Cipla Limited
Bausch & Lomb Corp.
Carl Zeiss Meditec
Santen Pharmaceuticals Co. Ltd.
Topcon Corporation
Thea Laboratoires
Corza Ophthalmology
Lumenis Ltd.
Alcon Inc.
Viva Bio À̳뺣ÀÌÅÍ
Glaukos Corporation
Iridex Corporation
Nova Eye Medical Ltd.
Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå
Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)
Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ
Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«
³ì³»Àå ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
³ì³»Àå ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
³ì³»Àå ½ÃÀå(2029³â) : ¼ºÀå Àü·«
½ÃÀå µ¿Çâ¿¡ ±Ù°ÅÇÑ Àü·«
°æÀï Àü·«
Á¦36Àå ºÎ·Ï
LSH
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
Glaucoma refers to a group of eye conditions that damage the optic nerve, typically due to increased intraocular pressure (IOP). If left untreated, this damage can lead to progressive and irreversible vision loss, making glaucoma one of the leading causes of blindness worldwide. Early detection through regular eye exams is essential to prevent vision impairment.
The primary types of glaucoma are open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma occurs when the eye's drainage angle remains open, but the trabecular meshwork becomes progressively blocked, resulting in elevated IOP. It can be diagnosed using various methods such as tonometry, ophthalmoscopy, perimetry, and gonioscopy. Treatment includes several drug classes, including beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs. These treatments are administered through oral medications, injections, intravitreal injections, and other routes, with end users such as hospitals, ophthalmic clinics, and ambulatory surgical centers.
The glaucoma market research report is one of a series of new reports from The Business Research Company that provides glaucoma market statistics, including glaucoma industry global market size, regional shares, competitors with a glaucoma market share, detailed glaucoma market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. This glaucoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glaucoma market size has grown strongly in recent years. It will grow from $7.76 billion in 2024 to $8.22 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to factors such as increasing awareness of eye health, rising healthcare spending, the growing adoption of telemedicine for eye care, expanding healthcare infrastructure, and increased government healthcare initiatives. These factors have contributed to better detection, treatment, and management of glaucoma, helping more individuals access the care they need.
The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.20 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period is expected to be driven by the aging population, rising prevalence of glaucoma, and the growing demand for minimally invasive surgeries. Additionally, the rising prevalence of conditions such as diabetes and hypertension, which are risk factors for glaucoma, will further fuel demand for glaucoma care. Major trends in the forecast period include advancements in diagnostic technologies, the availability of new drug treatments, innovations in surgical devices, the availability of combination therapies, and the increasing adoption of robotic surgeries, all of which will contribute to more effective and efficient glaucoma management.
The increasing prevalence of chronic eye conditions is expected to drive growth in the glaucoma market. Chronic eye conditions are long-lasting disorders that impact the eyes, often causing ongoing vision impairment or discomfort, necessitating continuous management or treatment. Factors contributing to the rise of these conditions include an aging population, more screen time, lifestyle changes, and higher rates of diseases such as diabetes and hypertension. Glaucoma treatment is essential for managing chronic eye conditions, as it helps lower intraocular pressure, prevents further damage to the optic nerve, and preserves vision, with untreated glaucoma potentially leading to irreversible blindness. For example, in December 2024, the National Health Service (NHS) reported that over 2 million people in the UK are living with sight loss, a number projected to grow by 27%, reaching approximately 2.8 million by 2035. As a result, the rising prevalence of chronic eye conditions is driving demand in the glaucoma market.
Leading companies in the glaucoma market are focusing on the development of innovative treatments, including Rho-kinase (ROCK) inhibitors, which provide a dual mechanism of action. These therapies reduce intraocular pressure by improving the outflow of aqueous humor and relaxing trabecular meshwork cells, making them highly effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors work by targeting and blocking the Rho-kinase enzymes, which regulate cell contraction and help decrease intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, designed to lower intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is intended for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with monotherapy involving prostaglandin or netarsudil. The launch of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, representing a significant advancement in treatment. By combining netarsudil and latanoprost, Roclanda enhances outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive solution for managing elevated IOP.
In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc., a U.S.-based developer of minimally invasive glaucoma surgery (MIGS) procedures. The acquisition is expected to enhance Bausch + Lomb's glaucoma treatment options by providing solutions that do not require implants. This move reflects the company's commitment to advancing technologies that support eye care professionals in addressing patients' evolving needs.
Major players in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG.
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glaucoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the glaucoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glaucoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on glaucoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glaucoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glaucoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
4) By Administration: Oral; Injections; Intravitreal; Other Administrations
5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Glaucoma Market Characteristics
3. Glaucoma Market Trends And Strategies
4. Glaucoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Glaucoma Growth Analysis And Strategic Analysis Framework
5.1. Global Glaucoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glaucoma Market Growth Rate Analysis
5.4. Global Glaucoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glaucoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glaucoma Total Addressable Market (TAM)
6. Glaucoma Market Segmentation
6.1. Global Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Open Angle Glaucoma
Angle Closure Glaucoma
Other Disease Types
6.2. Global Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tonometry
Ophthalmoscopy
Perimetry
Gonioscopy
6.3. Global Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Beta Blockers
Prostaglandins
Alpha Adrenergic Agonist
Carbonic Anhydrase Inhibitors
Combination Drugs
Other Drug Classes
6.4. Global Glaucoma Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injections
Intravitreal
Other Administrations
6.5. Global Glaucoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
6.6. Global Glaucoma Market, Sub-Segmentation Of Open Angle Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Open Angle Glaucoma (POAG)
Secondary Open Angle Glaucoma
6.7. Global Glaucoma Market, Sub-Segmentation Of Angle Closure Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Angle Closure Glaucoma
Secondary Angle Closure Glaucoma
6.8. Global Glaucoma Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal-Tension Glaucoma
Pigmentary Glaucoma
Pseudoexfoliative Glaucoma
Congenital Glaucoma
7. Glaucoma Market Regional And Country Analysis
7.1. Global Glaucoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glaucoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Glaucoma Market
8.1. Asia-Pacific Glaucoma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Glaucoma Market
9.1. China Glaucoma Market Overview
9.2. China Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Glaucoma Market
10.1. India Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Glaucoma Market
11.1. Japan Glaucoma Market Overview
11.2. Japan Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Glaucoma Market
12.1. Australia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Glaucoma Market
13.1. Indonesia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Glaucoma Market
14.1. South Korea Glaucoma Market Overview
14.2. South Korea Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Glaucoma Market
15.1. Western Europe Glaucoma Market Overview
15.2. Western Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Glaucoma Market
16.1. UK Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Glaucoma Market
17.1. Germany Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Glaucoma Market
18.1. France Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Glaucoma Market
19.1. Italy Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Glaucoma Market
20.1. Spain Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Glaucoma Market
21.1. Eastern Europe Glaucoma Market Overview
21.2. Eastern Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Glaucoma Market
22.1. Russia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Glaucoma Market
23.1. North America Glaucoma Market Overview
23.2. North America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Glaucoma Market
24.1. USA Glaucoma Market Overview
24.2. USA Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Glaucoma Market
25.1. Canada Glaucoma Market Overview
25.2. Canada Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Glaucoma Market
26.1. South America Glaucoma Market Overview
26.2. South America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Glaucoma Market
27.1. Brazil Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Glaucoma Market
28.1. Middle East Glaucoma Market Overview
28.2. Middle East Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Glaucoma Market
29.1. Africa Glaucoma Market Overview
29.2. Africa Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Glaucoma Market Competitive Landscape And Company Profiles
30.1. Glaucoma Market Competitive Landscape
30.2. Glaucoma Market Company Profiles
30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Glaucoma Market Other Major And Innovative Companies
31.1. Otsuka Pharmaceutical Co. Ltd.
31.2. Sun Pharmaceutical Industries Ltd.
31.3. Cipla Limited
31.4. Bausch & Lomb Corp.
31.5. Carl Zeiss Meditec
31.6. Santen Pharmaceuticals Co. Ltd.
31.7. Topcon Corporation
31.8. Thea Laboratoires
31.9. Corza Ophthalmology
31.10. Lumenis Ltd.
31.11. Alcon Inc.
31.12. Viva BioInnovator
31.13. Glaukos Corporation
31.14. Iridex Corporation
31.15. Nova Eye Medical Ltd.
32. Global Glaucoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Glaucoma Market
34. Recent Developments In The Glaucoma Market
35. Glaucoma Market High Potential Countries, Segments and Strategies
35.1 Glaucoma Market In 2029 - Countries Offering Most New Opportunities
35.2 Glaucoma Market In 2029 - Segments Offering Most New Opportunities